Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe
In light of SOT & ASCPT conference cancellations we’re hosting two immersive Live Stream Learning sessions covering Simulations Plus posters & presentations.
Simulations Plus announced today the launch of its COVID-19 ACT Program to provide expedited, expert consulting assistance in coronavirus research.
Our goal is to help our clients minimize or eliminate the questions posed by regulatory reviews while decreasing the cost and time it takes to develop detailed reports.
To improve the productivity of science-based research & development enterprises by delivering innovative modeling and simulation software and insightful consulting services.
Ensuring the safety of drug therapies by leveraging our expertise in the areas of drug-induced liver injury, metabolic diseases, and modeling and simulation.
Providing strategic pharmacology and pharmacometric consulting services, PK/PD model development with NONMEM, clinical trial simulations, exposure-response evaluations, dose justification strategies and related data management services.
While our focus for the solutions we provide was initially targeted for pharmaceutical research & development, we have earned a sound reputation in other markets as we develop stronger relationships with regulatory agencies like the U.S. FDA, U.S. EPA, EMA, PMDA, ECHA, and more.
Stay up-to-date with our upcoming conference attendance & presentations, application webinars, and training workshop courses.
Find out how your peers are applying our technology by reviewing journal articles describing various user case studies.